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Abstract
Background: Human epidermal growth factor receptor 2 (HER2) is the most crucial ErbB receptor tyrosine kinase
(RTK) family member in HER2-positive (refered to HER2-overexpressing) breast cancer which are dependent on or
“addictive” to the Phosphatidylinositol-3-kinase (PI3K) pathway. HER2-related target drugs trastuzumab and lapatinib
have been the foundation of treatment of HER2–positive breast cancer. This study was designed to explore the
relationship between PI3K pathway activation and the sensitivity to lapatinib in HER2–positive metastatic breast
cancer patients pretreated with anthracyclins, taxanes and trastuzumab.
Methods: Sixty-seven HER2-positive metastatic breast cancer patients were recruited into a global lapatinib
Expanded Access Program and 57 patients have primary tumor specimens available for determination of PI3K
pathway status. PTEN status was determined by immunohistochemical staining and PIK3CA mutations were
detected via PCR sequencing. All patients were treated with lapatinib 1250 mg/day continuously and capecitabine
1000 mg/m
2 twice daily on a 2-week-on and 1-week-off schedule until disease progression, death, withdrawal of
informed consent, or intolerable toxicity.
Results: PIK3CA mutations and PTEN loss were detected in 12.3% (7/57) and 31.6% (18/57) of the patients,
respectively. Twenty-two patients with PI3K pathway activation (defined as PIK3CA mutation and/or PTEN
expression loss) had a lower clinical benefit rate (36.4% versus 68.6%, P = 0.017) and a lower overall response rate
(9.1% versus 31.4%, P = 0.05), when compared with the 35 patients with no activation. A retrospective analysis of
first trastuzumab-containing regimen treatment data showed that PI3K pathway activation correlated with a shorter
median progression-free survival (4.5 versus 9.0 months, P = 0.013).
Conclusions: PIK3CA mutations occur more frequently in elder patients for HER2-positive breast cancer. PIK3CA
mutations and PTEN loss are not mutually exclusive. PI3K pathway activation resulting from PTEN loss or PIK3CA
mutations may lead to drug resistance to lapatinib and trastuzumab (http://ClinicalTrials.gov number,
NCT00338247).
Background
Human epidermal growth factor receptor 2 (HER2) is
the most crucial ErbB receptor tyrosine kinase (RTK)
family member in breast cancer with overexpression in
about one fourth of patients [1]. Since HER2 plays a key
role in HER2-positive breast cancer, these patients
usually have bad prognosis, and HER2-related target
drugs have been the foundation of treatment. Trastuzu-
mab, a HER2 monoclonal antibody against the extracel-
lular domain of the molecule, has been a new standard
in neo-adjuvant, adjuvant and palliative treatment of
HER2-positive breast cancer [1-3]. However, trastuzu-
m a bm o n o - t h e r a p ys h o w sar e s p o n s er a t eo fn om o r e
than 30% in palliative setting [4], and there is still a pro-
blem of primary or acquired resistance even with com-
bination regimens. HER2-overexpressing breast cancer
cells are dependent on or “addictive” to the Phosphati-
dylinositol-3-kinase (PI3K) pathway [5]. Published litera-
tures showed that PI3K pathway activation is associated
with primary resistance to trastuzumab, and
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sence of a normal PI3K pathway [6-11].
PI3K pathway is one of the most important signaling
pathways in cell, which is involved in many fundamental
cellular processes, including proliferation, cell survival,
motility and cell growth [12,13]. Class IA PI3K, the
most important member of the PI3K complex, is com-
posed of a heterodimer with a p85 regulatory subunit
and a p110 catalytic subunit (PIK3CA), residing down-
stream of multiple receptor kinase families including
ErbB RTK family (EGFR, HER2, HER3, HER4) and
transducing signals originating from them [12,13]. Phos-
phatase and tensin homolog deleted on chromosome 10
(PTEN) is a phosphotase that converts membrane-asso-
ciated phosphatidylinositol 3,4,5-triphosphate (PIP3)
back to phosphatidylinositol 4,5-bisphosphate (PIP2)
and negatively regulates signaling transduction of PI3K
pathway [14,15]. It is well known that dysregulation of
PI3K pathway plays an important role in the develop-
ment of malignancy, and the most common genetic
alterations in this pathway are PIK3CA mutation and
PTEN loss [16,17], both of which can lead to constitu-
tive activation of PI3K pathway and resistance to trastu-
zumab [7]. PTEN-related resistance to trastuzumab can
be reversed by combined treatment with trastuzumab
and the PI3K inhibitor LY294002 [18]. Therefore, PI3K
pathway activation resulting from PIK3CA mutation
and/or PTEN loss warrants further studies.
Up to now, little knowledge is available about the cor-
relation between PI3K pathway status and efficacy and
resistance of the other FDA-approved anti-HER2 agent,
lapatinib. Laptinib, a dual tyrosine kinase inhibitor of
EGFR and HER2, binds to the intracellular kinase
domain [19]. It has no cross-resistance with trastuzumab
since it is effective against breast cancer expressing
p95HER2 [20], an active truncated form of HER2 and
with HER2 epitope masked by mucin 4 [21]. Clinical
data have shown the safety and efficacy of lapatinib
alone and in combination with capecitabine, paclitaxel
and letrozole and it is still effective in patients who have
progressed on trastuzumab [22-24]. Therefore, the
HER2 pathway is still an “addictive” oncogenic pathway
in breast cancer pretreated with trastuzumab. However,
several recent papers touching on PI3K pathway activa-
tion and lapatinib resistance conflicted with each other
[18,25-29], so we conducted this study to explore their
correlation and the protocol was approved by the Fudan
University Shanghai Cancer Center Institutional review
board on June 30, 2008.
Methods
Patient Eligibility and Study Design
A global lapatinib Expanded Access Program was started
to offer preapproval drug in order to provide clinical
benefit to patients with HER2-positive metastatic breast
cancer who had progressive diseases on treatment with
regimens including anthracyclines, taxanes, and trastu-
zumab. Trastuzumab had to be used in metastatic set-
ting. Tumors with either 3+ immunohistochemical
staining for HER2 protein or HER2 gene amplification
by fluorescence in situ hybridization were defined as
HER2 positive in our institution. Women previously
treated with capecitabine were eligible. Patients were
required to have evaluable disease according to the
Response Evaluation Criteria in Solid Tumors (RECIST);
an Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0 or 1; a left ventricular ejection frac-
tion (LVEF) within the institution’sn o r m a lr a n g e ;al i f e
expectancy of at least 12 weeks; and adequate renal,
hepatic, and hematologic function. patients with central
nervous system (CNS) metastases were eligible if they
were clinically stable for at least 3 months after disconti-
nuation of radiation therapy. patients with preexisting
heart disease or conditions that could affect gastrointest-
inal absorption were ineligible. All patients gave written
informed consent on recruitment into the global lapati-
nib Expanded Access Program and provision of the pri-
mary tumor sample for this translational study(http://
ClinicalTrials.gov number, NCT00338247).
In this one-arm study, all patients receive the combi-
nation regimen consisting of lapatinib at a dose of 1250
mg daily on a continuous basis and capecitabine at a
dose of 2000 mg per square meter of body-surface area
in two divided doses on days 1 through 14 of a 21-day
cycle. Standard recommendations for capecitabine
dosage modifications were followed in the management
of adverse events. Lapatinib was withheld for up to 14
days for grade 2 or more nonhematologic toxicity or
any grade 3 or 4 hematologic toxicity. Patients were
assessed every 6 weeks for the first 24 weeks, and then
every 12 weeks while they were still receiving the study
treatment. Patients who had no progressive disease but
whose study treatment was withdrawn were assessed
every 12 weeks until the commencement of alternative
anticancer treatment, disease progression, or death. Effi-
cacy was determined according to the RECIST criteria.
Adverse events were assessed according to the National
Cancer Institute’s Common Terminology Criteria for
Adverse Events (CTCAE, version 3.0). The clinical bene-
fit was defined as a complete response, partial response,
or stable disease for at least 6 months. Progression-free
survival was calculated as the interval between the date
of signing informed consent and the date of disease pro-
gression, or death from any cause.
PCR Sequencing and PIK3CA Mutation
DNA was extracted from formaldehyde-fixed, paraffin-
embedded tumor tissue. PCR were performed with 10
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standard protocol. PIK3CA gene PCR primers were E9F
CAAAGCAATTTCTACACGAGATCC; E9R GTAAA
AACATGCTGAGATCAGCCACAT; E20F TGGAAT
GCCAGAACTACAATCTTT; E20R GGTCTTTGCC
TGCTGAGAGTT. The PCR products were sequenced
using the ABI3130XL automated capillary sequencer by
Shanghai Tianhao Biotechnology Company.
Immunohistochemistry and PTEN Scoring
T h ea n t i b o d yf o rP T E NI H Cs t a i n i n gw a sar a b b i t
monoclonal anti-PTEN (D4.3) XPTM (Cell Signaling
Beverly, MA, USA) diluted 1:200. The antibody was
applied overnight at 4ºC. Then the tissues were incu-
bated with the second antibody (1:500, Jackson lab) for
30 min. The color was developed with DAB solution
a b o u t1m i na tr o o mt e m p e r a t u r ea n dt h e ns t a i n e di n
Harris hematoxylin solution for 3 min. Each set of slides
included positive and negative control slides and normal
cells in a tumor were used as an internal control.
PTEN immunoreactivity was examined by two inde-
pendent observers who were blinded to the clinical data.
A third pathologist was invited when the discordance
was present between them. The staining was mainly
visible in the cytoplasm of tumor cells. PTEN expression
levels were semiquantified using immunoreactive scores
(IRS) calculated by multiplying the percentage of PTEN-
positive tumor cells (scored 0 to 4) with the PTEN
staining intensity [1-3]. The tumor was graded as
PTEN-negative (IRS 0-3), weak positive (IRS 4-6), posi-
tive (IRS 7-9), and strong positive (IRS 10-12)[6].
Statistical Analysis
The relationships between different variables were
assessed by Chi-square tests and the trends were also
examined by Chi-square tests when required. Differ-
ences in progression-free survival (PFS) and overall
survival (OS) between groups were determined using
the log-rank test. After a univariate analysis, the vari-
ables with significant correlation with PFS and OS,
continuous variables and PI3K pathway status were put
in a Cox proportional hazard regression model to
determine which was an independent prognostic factor
for PFS and OS, respectively. The statistical difference
was considered significant if the P value was less than
0.05.
Results
Patient Characteristics
Sixty-seven Chinese patients were enrolled from Fudan
University Cancer Center from Aug. 2008 to Mar. 2010.
The median age was 49.0 years old (range 26-75). Fifty-
seven patients had their tumor tissues available for
detection of PI3K pathway activation (PIK3CA mutation
and PTEN expression loss). Clinical and pathological
data for the patients are showed in Table 1.
PIK3CA mutation and PTEN expression loss
The overall incidence of PIK3CA mutations was 12.3%
(7 in 57 samples). The majority of mutations occurred
at two hotspots, H1047R (7%, 4 samples) at exon 20
encoding the kinase domain (Figure 1a), and E542K
(1.8%, 1 sample) at exon 9 encoding the helical domain
(Figure 1b). L540F and T1052A mutations are rare and
each was found in one tumor sample (Figure 1c-d).
PTEN expression loss was found in 18 patients (31.6%,
Figure 2a). Thirty-nine patients were positive for PTEN
expression [6], in which 17 (29.8%), 14 (24.6%), and 8
(14%) specimens were weak positive, positive and strong
positive respectively (Figure 2b-d). In this study, PTEN
loss was not mutually exclusive with PIK3CA mutations,
since 3 of the 4 patients with H1047R mutation were
also found to have no PTEN expression (Table 2).
Compared with the wild type, PI3K pathway activation
(PIK3CA mutation and/or PTEN expression loss) was iden-
tified in a significantly older patient population (P = 0.016).
The median age of patients with the PI3K pathway activa-
tion was 53.6 ± 7.9 years, while the median age of those
with no PI3K pathway activation was 47.0 ± 10.9 years. The
PI3K pathway activation status was not associated with all
other clinicopathological parameters, such as hormone
receptor status, HER2 protein expression status and disease
free interval after radical mastectomy (all P > 0.05).
Patient outcome and PI3K pathway activation
On September 30, 2010, preliminary analysis was made
on the basis of 50 disease progression events and 28
deaths. Median follow-up time was 15.3 ± 6.3 months.
The median PFS of all 67 patients was 6.5 months (95%
CI, 5.7-7.3 months), and the median PFS of the 57
patients who provided their tumor tissues for detection
of PI3K pathway activation was also 6.5 months (95%CI,
5.4-7.6 months). The overall response rate (complete
response plus partial response) was 22.4% for all 67
patients and 22.8% for the 57 patients whose tumor
sample were available. The corresponding clinical bene-
fit rates were 58.2% and 56.1%. The median overall sur-
vivals for both cohorts were 17.0 months.
An analysis of our data showed that PIK3CA mutation
didn’t correlate with overall response rate, clinical bene-
fit rate or progression-free survival. For PTEN expres-
sion status, patients with wild type gene enjoyed a
clinical benefit rate of 66.7%, which was statistically
higher than 33.3% in those with no PTEN expression (P
= 0.018). The overall response rate of 28.2% and median
PFS of 8 months in the patients with PTEN expression
were substantially higher, although the differences were
not statistically significant (Table 3). When analyzing
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since both can activate PI3K pathway, the clinical bene-
fit was still observed for patients with no activation of
PI3K pathway (68.6% versus 36.4%, P = 0.017; Figure 3).
The overall response rate was also higher (31.4% versus
9.1%, P = 0.05; Figure 3). Both overall response and clin-
ical benefit significantly correlated with PFS (Figure 4a-
b), however, there was no significant association of PI3K
pathway activation status with PFS or OS (Figure 4c).
A retrospective analysis was done to explore the rela-
tionship between PI3K pathway activation status and the
efficacy of the other anti-HER2 drug, trastuzumab. We
chose the progression-free survival of the first trastuzu-
mab-containing regimen as an indicator for trastuzumab
efficacy. The regimens were trastuzumab combined with
one or two chemotherapy drugs, including docetaxel,
vinorelbine, paclitaxel, gemcitabine, capecitabine and
cisplatin. As previously reported, PI3K pathway activa-
tion shortened the median progression-free survival sig-
nificantly (4.5 versus 9.0 months, P = 0.013; Figure 4d).
PTEN expression status had a similar differentiating
effect (6.0 versus 9.0 months, P = 0.024). However, the
difference of PFS (4.5 versus 8.0 months) resulting from
PIK3CA mutation wasn’t significant.
Patient outcome and other factors
Response and survival of breast cancer might be affected
by many other factors, such as age, ECOG performance
Table 1 Patient Characteristics
Characteristics All Patients Patients analyzed P value
No. Percent No. Percent
Age, (yrs)
Median(IQR) 49.0 (46.5-51.4) 49.5 (46.8-52.3) P > 0.05
Range 26-75 26-75
EOCG performance status
0 12 17.9% 10 17.5% P > 0.05
1 49 73.1% 45 79.0%
2 6 9.0% 2 3.5%
Hormone receptor status
ER(+) or PR(+) or Both 29 43.3% 25 43.8% P > 0.05
ER(-) and PR(-) 38 56.7% 32 56.2%
HER2 expression by IHC
1+/2+ (HER2 status confirmed by FISH) 22 32.8% 20 35.1% P > 0.05
3+ positive 45 67.2% 37 64.9%
Number of involved sites
1 16 23.9% 13 22.8% P > 0.05
2 23 34.3% 22 38.6%
≥3 28 41.8% 22 38.6%
Location of involved sites
Visceral only 19 28.4% 16 28.1% P > 0.05
Visceral and nonvisceral 34 50.7% 29 50.9%
Nonvisceral only 14 20.9% 12 21.0%
Involved organs
Lung 29 43.3% 26 45.6% P > 0.05
Liver 26 38.8% 23 40.4%
Brain 18 26.9% 14 24.6%
Previous chemotherapy regimens
1 16 23.9% 13 22.8% P > 0.05
2 22 32.8% 20 35.1%
≥3 29 43.3% 24 42.1%
Previous capecitabine
YES
Progression during capecitabine 35 52.2% 29 50.9% P > 0.05
No Progression during capecitabine 11 16.4% 10 17.5%
NO 21 31.3% 18 31.6%
Legend: ER, estrogen receptor; PR, progesterone receptor; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization
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static sites, number of metastatic sites and previous
treatments. A univariate analysis of our data showed
that only number of metastatic sites had a negative
impact on overall response rate of the lapatinib and
capecitbine doublet, while none of the above-mentioned
factors was statistically associated with clinical benefit
rate. Concerning survival, only previous capecitabine
treatment was statistically associated with a shorter PFS
(6.5 vs. 11.0 months, P = 0.011, Table 4) and OS (14.0
months vs. not reached, P = 0.003).
We put all the above-mentioned variants of PI3K
pathway status, age and clinical benefit status into Cox’s
proportional hazards model to investigate how much
PI3K pathway activation affected patient outcome. Clini-
cal benefit rate was the only independent factor for PFS
in HER2-positive breast cancer.
Discussion
PI3K pathway activation is the most common signal
transduction pathway alteration in malignancies, includ-
ing breast cancer [30]. It mostly results from PIK3CA
mutation or amplification, PTEN loss [16]. Since the
patients enrolled in this study were HER2-positive and
high-level PIK3CA amplification without mutation is
rare in this subpopulation [31,32], so only PIK3CA
mutation and PTEN loss were determined for the sam-
ples in our study.
Our data showed that PIK3CA mutation occurred in
12.3% of the patients, lower than 8-40% reported in
other studies [33-38]. There are several reasons. First,
only two exons accounting for approximately 85% of all
Figure 1 PTEN gene mutations. Sample 38, 46, 65, 68 have exon
20 missense mutations, H1047R (a); sample 2 has exon 9 missense
mutation, E542K (b); sample 11 has exon 9 missense mutation,
L540F (c); sample 54 has exon 20 missense mutation, T1052A (d).
Figure 2 PTEN expression. PTEN negative (IRS 0-3, a); Weak Positive (IRS 4-6, b); Positive (IRS 7-9, c); and Strong Positive (IRS 10-12, d).
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mutation correlates with an old age and this phenom-
enon was confirmed by our study [39]. However, the
median age of our patients was 49.0 years, about 10
years younger than Caucasian counterparts [39]. Third,
the mutation was reported to occur more frequently in
HER2-negative patients [39,40], however, all patients in
our study were HER2-positive.
Regarding mutations in hot spots, two common muta-
tion points, H1047R and E542K were also present in our
patients with no mutation of E545K observed [37,39]. As
to mutations in non-hot spots, two new points, L540F
and T1052A mutations were first reported based on our
knowledge. An analysis of our data showed that the ratio
of hot spots to non-hot spots was 2.5 to 1, which is con-
sistent with other reports [39]. Since there were only a
few patients with the new mutation, our result needed
further confirmation by other studies. Therefore, it
remains a question whether the new mutation in non-hot
spots results in an activation of PI3K pathway. As in
other studies, these patients were considered to have a
mutated gene in the analysis [39].
PTEN is a tumor suppressor gene, and can be down-
regulated or lost of expression via deletion (common in
breast cancer), mutation (rare in breast cancer), or pro-
moter DNA methylation [14,41,42]. Loss of PTEN
expression results in activation of PI3K pathway leading
to development of cancer [15,41]. PTEN loss is present
in about one third of breast cancer patients, ranging
from 15% to 48% [43-46]. Our study showed that the
incidence of PTEN loss was 31.6%, which is consistent
with other reported results.
Previous reports suggested that PIK3CA mutation and
PTEN loss were mutually exclusive [37]. However, in 4
patients with H1047R mutations in our study, 3 patients
were also found to have no PTEN expression. This fact
was previously reported by Perez-Tenorio et al in 2009
[40]. PI3K mutation was indicated to be associated with
ER positivity, HER2 negativity and primary tumor size,
which were not observed in our study [37,39,40].
An analysis of our data showed that patients with
PI3K pathway activation had a statistically significant
shorter median PFS than those with no PI3K pathway
activation (4.5 versus 9.0 months, P = 0.013), confirming
the reported conclusion that PI3K pathway activation
can result in resistance to trastuzumab [6-10]. Based on
the published preclinical studies, these patients should
be sensitive to lapatinib, a drug with a different mechan-
ism of action [47]. There were some clinical data
demonstrating that lapatinib induced objective responses
in patients who had failed trastuzumab [22]. However,
all patients were treated with lapatinib and capecitabine
in our study, and PI3K pathway activation was still cor-
related with a lower clinical benefit rate (36.4% versus
68.6%, P = 0.017) and a lower overall response rate
(9.1% versus 31.4%, P = 0.05), which is consistent with
results of a smaller study reported by Cizkova et al [48].
Campone [49] et al pointed out that acquisition of resis-
tance is frequently linked to an uncoupling between
Table 2 Summary of PI3KCA mutations and PTEN
expression
PI3KCA mutations Wild
Type
Total
PTEN
expression
Exon 20 Exon 9
(IHC score) H1047R T1052A E542K L540F
negative 3 0 0 0 15 18
weak positive 1 0 0 0 16 17
positive 0 1 1 0 12 14
strong
positive
00 01 7 8
Total 4 1 1 1
Legend: IHC, immunohistochemistry
Table 3 PI3K pathway activation and Efficacy of HER2-Targeted Drugs
PI3KCA mutation PTEN expression PI3K pathway activation
Mutation (n = 7) WT
(n = 50)
P Loss
(n = 18)
WT
(n = 39)
P Activation (n = 22) WT
(n = 35)
P
Lapatinib plus Capecitabine
Overall response
No.(%)
1
(14.3%)
12
(24%)
NS 2
(11.1%)
11
(28.2%)
NS 2
(9.1%)
11
(31.4%)
0.050
Clinical benefit
No. (%)
3
(42.9%)
29
(58%)
NS 6
(33.3%)
26
(66.7%)
0.018 8
(36.4%)
24
(68.6%)
0.017
Median PFS
months (95% CI)
6
(2.7-9.3)
6.5
(4.3-8.7)
NS 5
(4.0-6.0)
8
(5.6-10.4)
NS 5
(3.5-6.6)
8
(5.1-10.9)
NS
Median OS
months (95% CI)
17
(2.5-31.5)
17
(11.8-22.2)
NS 19.5 15 NS 19.5 15 NS
First Trastuzumab Regimen
Median PFS
months (95% CI)
4.5
(0.7-8.3)
8
(5.2-10.8)
NS 6
(3.3-8.7)
9
(7.1-10.9)
0.024 4.5
(2.0-7.0)
9 (7.6-10.4) 0.013
Legend: NS, not significant; WT, wildtype gene
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stream signals related to PI3K, AKT and/or MAPK. Two
studies showed that both knockdown of PTEN and
transfection of mutant PIK3CA can result in lapatinib
resistance and the mTOR/PI3K inhibitor, NVP-BEZ235
can reverse the resistance [26,50].
However, there are also a few converse opinions.
Based on the experimental results, O’Brien et al
showed that lapatinib could overcome trastuzumab
resistance via continued deactivation of PI3K/AKT/
mTOR signaling [51]. A Japanese clinical study recruit-
ing 122 patients attempted to illustrate the relationship
between PI3K pathway activation and efficacy of lapati-
nib, but PIK3CA mutation was only found in 3 tissue
samples among all 29 analyzed samples [52]. Recently,
Toi et al indicated that low PTEN could predict
response to lapatinib in a small phase 2 neoadjuvant
Figure 3 Overall response rate (ORR) and clinical benefit rate
(CBR) grouped by the status of PI3K pathway activation. The
ORR was marginally significant between pathway activation group
and wild type group; the CBR was statistically significant between
pathway activation and wild type groups.
Figure 4 Progression-free survival with objective response, clinical benefit, and PI3K pathway activation. The difference in PFS between
patients with response (CR+PR) and those without response (a); the difference in PFS between patients with clinical benefit (CR+PR+SD > 6
months) and those without benefit (b); the difference in PFS between patients with pathway activation and those with no activation (c), and
pathway activation status with efficacy of the first Trastuzumab-containing regimen (d).
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the PI3K pathway status and anti-HER2 therapy cannot
be drawn up to now, and our study justifies further
research.
It remains controversial whether the two gene altera-
tions have any prognostic value. Li et al suggested that
PIK3CA mutation was a negative prognostic factor [35].
On the contrary, a larger sample size study and a Japa-
nese study indicated that it was a positive prognostic
factor [36,39]. Barbareschi [54] et al reported that muta-
tion in exon 20 usually indicated good prognosis, while
t h em u t a t i o ni ne x o n9o f t e nm e a n tb a dp r o g n o s i s .
Perez-Tenorio [40] et al suggested that the two gene
alterations should be combined with S phase fraction to
give an accurate prediction of prognosis. Recently,
Dupont Jensen [55] et al showed that there is a discre-
pancy of PIK3CA mutation between primary and meta-
static tumors, urging on a simultaneous detection of the
two matched samples. For the prognostic value of
PTEN, it is relatively uniform and most investigators
thought that PTEN loss is a negative prognostic factor
[56,57]. Our data showed that it was statistically
associated with clinical benefit rate (P = 0.021). Due to
a relatively smaller sample size of our study, no signifi-
cant correlations between PI3K pathway status and clin-
icopathological parameters were found.
Conclusions
In conclusion, PIK3CA mutation occurs more frequently
in elder patients and the ratio of mutations in hot spots
to non-hot spots is about 2.5 to 1 in HER2-positive
breast cancer patients. PTEN loss is present in about
one third of patients. PIK3CA mutation and PTEN loss
were not mutually exclusive. PI3K pathway activation
may lead to drug resistance to lapatinib as well as
trastuzumab.
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